ROLE OF NEUROPEPTIDE GALANIN IN THE PATHOGENESIS OF TYPE 2 DIABETES MELLITUS
Main Article Content
Keywords
Type-2 DM, Galanin, Insulin, Insulin resistance, Galanin resistance
Abstract
Introduction: In this study, the characteristic milestones of type 2 diabetes mellitus were condensed as two analogical models, insulin resistance-type 2 diabetes mellitus and galanin resistance-type 2 diabetes mellitus. Galanin resistance and insulin resistance should be related to each other. Obesity and BMR along with other factors which are components of syndrome X should have a relation to both insulin resistance and galanin resistance.
Aim & Objective: Aim is to determine the accuracy of circulating galanin for early prediction of Type 2 Diabetes Mellitus. Objective is to assess the comparative serum level of galanin in patients with type-2 diabetes mellitus and healthy controls along with the correlation of serum galanin level with Insulin Resistance & the risk factors of type-2 diabetes mellitus.
Material & Method: This study was conducted in the Department of Pharmacology & Therapeutics at King George’s Medical University (KGMU), Lucknow. Patients registered in OPD of the Department of Medicine, King George’s Medical University, Lucknow who were diagnosed to be the cases of T2DM were screened based on selection criteria for the study. Controls were screened among healthy men and women between 18-60 years of age who have not been diagnosed with any physical or psychological illness for which they are not on any kind of regular medication. A total of 50 healthy individuals of similar ethnicity from North India were recruited as controls. 50 selected cases as well as controls were subsequently called for sample collection on the next day in a fasting state.
Result: This study shows that the level of serum galanin is significantly higher in Type-2 Diabetes Mellitus patients as compared to healthy controls in the North Indian population. The Body Mass Index, Waist-to-Hip ratio, Systolic Blood Pressure, Diastolic Blood Pressure, Fasting Blood Sugar, Total Cholesterol, Triglycerides, and LDL-C are significantly higher in type-2 diabetic mellitus patients as compared to healthy controls. The level of HDL-C is higher in healthy controls than in Type-2 Diabetes patients. Fasting Insulin level and Insulin resistance index (HOMA-IR) was found to be significantly higher in Type-2 Diabetes patients as compared to healthy controls. Pancreatic β-cell index (HOMA-B) levels of healthy controls were found to be significantly higher than that of Type-2 Diabetic patients. A strong positive correlation of Galanin was observed with Weight, BMI, Triglyceride levels, Insulin and HOMA-IR levels. A moderate correlation of Galanin was observed with Fasting Blood Sugar and HbA1C. Galanin did not show any correlation with age and LDL levels of the study population.
Conclusion: An optimum cut-off value for serum Galanin above 19.135 pg/ml is predictive of Type-2 Diabetes Mellitus with 86.0% Sensitivity and 78.0% Specificity.
References
2. Laios K, Karamanou M, Saridaki Z, Androutsos G. Aretaeus of Cappadocia and the first description of diabetes. Hormones. 2012 Jan;11(1):109-13.
3. Morton GJ, Meek TH, Schwartz MW. Neurobiology of food intake in health and disease. Nature Reviews Neuroscience. 2014 Jun;15(6):367-78.
4. Russo AF. O verview of N europeptides: A wakening the S enses?. Headache: The Journal of Head and Face Pain. 2017 May;57:37-46.
5. Evans H, Baumgartner M, Shine J, Herzog H. Genomic organization and localization of the gene encoding human preprogalanin. Genomics. 1993 Dec 1;18(3):473-7.
6. Tatemoto K, Rökaeus Å, Jörnvall H, McDonald TJ, Mutt V. Galanin—a novel biologically active peptide from porcine intestine. FEBS letters. 1983 Nov 28;164(1):124-8.
7. Mechenthaler I. Galanin–25 years with a multitalented neuropeptide. Cellular and Molecular Life Sciences. 2008 Jun;65(12):1826-35.
8. Lang R, Gundlach AL, Kofler B. The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacology & therapeutics. 2007 Aug 1;115(2):177-207.
9. Fang P, Bo P, Shi M, Yu M, Zhang Z. Circulating galanin levels are increased in patients with gestational diabetes mellitus. Clin Biochem2013;46:831
10. Legakis I, Mantzouridis T, Mountokalakis T. Positive correlation of galanin with glucose in type 2 diabetes. Diabetes Care 2005;28:759–60.
11. Zhang Z, Gu C, Fang P, Shi M, Wang Y, Peng Y, et al. Endogenous galanin as a novel biomarker to predict gestational diabetes mellitus. Peptides 2014;54:186–9.
12. Legakis IN. The role of galanin in metabolic disorders leading to type 2 diabetes mellitus.Drug News Perspect 2005;18:173–7.
13. Bu L, Liu Z, Zou J, Gao X, Bao Y, Qu S. Blocking central galanin receptors attenuates insulin sensitivity in myocytes of diabetic trained rats. J Neurosci Res 2013;91:971–7.
14. Guo L, Shi M, Zhang L, Li G, Zhang L, Shao H, Fang P, Ma Y, Li J, Shi Q, Sui Y. Galanin antagonist increases insulin resistance by reducing glucose transporter 4 effect in adipocytes of rats. General and comparative endocrinology. 2011 Aug 1;173(1):159-63.
15. He B, Shi M, Zhang L, Li G, Zhang L, Shao H, Li J, Fang P, Ma Y, Shi Q, Sui Y. Beneficial effect of galanin on insulin sensitivity in muscle of type 2 diabetic rats. Physiology &behavior. 2011 Jun 1;103(3-4):284-9.
16. Jiang L, Shi M, Guo L, He B, Li G, Zhang L, Zhang L, Shao H. Effect of M35, a neuropeptide galanin antagonist on glucose uptake translated by glucose transporter 4 in trained rat skeletal muscle. Neuroscience letters. 2009 Dec 25;467(2):178-81.
17. Liang Y, Sheng S, Fang P, Ma Y, Li J, Shi Q, Sui Y, Shi M. Exercise-induced galanin release facilitated GLUT4 translocation in adipocytes of type 2 diabetic rats. Pharmacology Biochemistry and Behavior. 2012 Jan 1;100(3):554-9.
18. Tang G, Wang Y, Park S, Bajpayee NS, Vi D, Nagaoka Y, Birnbaumer L, Jiang M. Go2 G protein mediates galanin inhibitory effects on insulin release from pancreatic β cells. Proceedings of the National Academy of Sciences. 2012 Feb 14;109(7):2636-41.
19. Ahrén B, Pacini G, Wynick D, Wierup N, Sundler F. Loss-of-function mutation of the galanin gene is associated with perturbed islet function in mice. Endocrinology. 2004 Jul 1;145(7):3190-6.
20. Zorrilla EP, Brennan M, Sabino V, Lu X, Bartfai T. Galanin type 1 receptor knockout mice show altered responses to high-fat diet and glucose challenge. Physiology &behavior. 2007 Aug 15;91(5):479-85.
21. Poritsanos NJ, Mizuno TM, Lautatzis ME, Vrontakis M. Chronic increase of circulating galanin levels induces obesity and marked alterations in lipid metabolism similar to metabolic syndrome. International Journal of Obesity. 2009 Dec;33(12):1381.
22. Mitsukawa K, Lu X, Bartfai T. Galanin, galanin receptors, and drug targets. Galanin. 2010:7-23.
23. Genders SG, Scheller KJ, Djouma E. Neuropeptide modulation of addiction: Focus on galanin. Neuroscience &Biobehavioral Reviews. 2020 Mar 1;110:133-49.
24. Kuteeva E, Hökfelt T, Wardi T, Ögren SO. Galanin, galanin receptor subtypes and depression-like behaviour. Galanin. 2010:163-81.
25. Hobson SA, Bacon A, Elliot-Hunt CR, Holmes FE, Kerr NC, Pope R, Vanderplank P, Wynick D. Galanin acts as a trophic factor to the central and peripheral nervous systems. Galanin. 2010:25-38.
26. Xu XJ, Hökfelt T, Wiesenfeld-Hallin Z. Galanin and spinal pain mechanisms: past, present, and future. Galanin. 2010:39-50.
27. Wu Z, Autry AE, Bergan JF, Watabe-Uchida M, Dulac CG. Galanin neurons in the medial preoptic area govern parental behaviour. Nature. 2014 May;509(7500):325-30.
28. Ruczynski J, Konstanski Z, Cybal M, Kocic I, Rekowski P. Aspartimide modified galanin analogue antagonizes galanin action on insulin secretion. Protein and peptide letters. 2010 Oct 1;17(10):1182-8.
29. Fang P, Yu M, Guo L, Bo P, Zhang Z, Shi M. Galanin and its receptors: a novel strategy for appetite control and obesity therapy. Peptides. 2012 Aug 1;36(2):331-9.
30. Zhang Z, Fang P, Yu M, Wang Y, Li Y, Shi M, Bo P, Gu X, Zhu Y. Serum Galanin Concentration is Increased in Subjects with Impaired Glucose Tolerance. Can J Diabetes. 2017 Dec;41(6):563-566. doi: 10.1016/j.jcjd.2017.01.001. Epub 2017 Apr 14. PMID: 28416367.
31. Alotibi MN, Alnoury AM, Alhozali AM. Serum nesfatin-1 and galanin concentrations in the adult with metabolic syndrome: relationships to insulin resistance and obesity. Saudi Medical Journal. 2019;40(1):19.
32. Sandoval-Alzate HF, Agudelo-Zapata Y, González-Clavijo AM, Poveda NE, Espinel-Pachón CF, Escamilla-Castro JA, Márquez-Julio HL, Alvarado-Quintero H, Rojas-Rodríguez FG, Arteaga-Díaz JM, Eslava-Schmalbach JH. Serum galanin levels in young healthy lean and obese non-diabetic men during an oral glucose tolerance test. Scientific reports. 2016 Aug 23;6(1):1-9.
33. Acar S, Paketçi A, Küme T, Demir K, Çalan ÖG, Böber E, Abaci A. Positive correlation of galanin with insulin resistance and triglyceride levels in obese children. Turkish journal of medical sciences. 2018 Jun 14;48(3):560-8.
34. Fang P, Yu M, Shi M, He B, Zhang Z, Bo P. The neuropeptide galanin benefits insulin sensitivity in subjects with type 2 diabetes. Current Protein and Peptide Science. 2013 Dec 1;14(8):669-73.
35. Fang P, Shi M, Zhu Y, Bo P, Zhang Z. Type 2 diabetes mellitus as a disorder of galanin resistance. Experimental gerontology. 2016 Jan 1;73:72-7.
36. Abot A, Lucas A, Bautzova T, Bessac A, Fournel A, Le-Gonidec S, Valet P, Moro C, Cani PD, Knauf C. Galanin enhances systemic glucose metabolism through enteric Nitric Oxide Synthase-expressed neurons. Mol Metab. 2018 Apr;10:100-108. doi: 10.1016/j.molmet.2018.01.020. Epub 2018 Jan 31. PMID: 29428595; PMCID: PMC5985240.
37. Yuqing She et al. Cardioprotective effects of neuropeptide galanin: Focusing on its roles against diabetic heart. Peptides. 2023; Volume 159: 170918.
38. Daniel M. Gallagher, Finbarr P.M. O’Harte, Nigel Irwin. An update on galanin and spexin and their potential for the treatment of type 2 diabetes and related metabolic disorders. Peptides. 2024; Volume 171: 171096.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Rohit Kumar Mishra
Senior Resident, Department of Pharmacology, All India Institute of Medical Sciences, Gorakhpur, Uttar Pradesh, India.
Dr. Stuti Singh
Assistant Professor, Department of Pharmacology, Uma Nath Singh Autonomous State Medical College, Jaunpur, India.
Dr. Palash Ratna
Assistant Professor, Department of Pharmacology, Uma Nath Singh Autonomous State Medical College, Jaunpur, India.
Dr. Sanjay Khattri
Professor, Department of Pharmacology & Therapeutics, K.G.M.U, Lucknow, Uttar Pradesh. India.
Dr. Richa Mishra
Chief Medical Officer-Selection Grade, Department of Pediatrics, Referral Hospital, ITBP, Lakhnawali, Greater Noida, Gautam Buddh Nagar, Uttar Pradesh, India